Conclusions:
In people without diabetes, metformin increases total GLP-1 in a sustained manner and independently of changes in weight or glycaemia. Metformin-treated patients with T2DM also have higher fasted GLP-1 levels, independently of weight and glycaemia.
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| INTRODUCTION
Metformin is recommended as first-line therapy for the majority of individuals with type 2 diabetes mellitus (T2DM). 1 This is based on evidence of cardiovascular benefit and also its capacity to maintain or reduce weight. In the UK Prospective Diabetes Study, metformin monotherapy led to a 39% reduction in the risk of myocardial infarction compared with conventional dietary therapy over 10 years, a finding not explained by the drug's effect on glycaemia. 2 Metformin has also been shown to reduce the risk of developing T2DM. In the Diabetes Prevention Program, metformin therapy reduced new-onset T2DM by 31% and also led to 2.1-kg weight loss compared with placebo over 2.8 years.
3,4
The glucagon-like peptide-1 (GLP-1) axis remains at the forefront of T2DM and cardiovascular research. Major outcomes trials of dipeptidyl peptidase-4 (DPP-4) inhibitors and the first completed outcome trial of a GLP-1 receptor agonist in patients with T2DM indicated cardiovascular safety, although not benefit [5] [6] [7] [8] ; however, it was recently reported that the potent GLP-1 receptor agonist, liraglutide, has cardiovascular benefit. 9 Furthermore, it has been reported that another GLP-1 receptor agonist, semaglutide, has also provided cardiovascular benefit in a major trial. 10 This is supported by recently published results from a Mendelian randomization study of a GLP-1 genetic variant (Ala316Thr; rs10305492) strongly associated with lower fasting glucose levels, which demonstrated a lower risk of cardiovascular disease, 11 supporting the concept that GLP-1 may indeed be protective against cardiovascular disease. In addition, GLP-1 receptor agonists can yield modest weight loss 12 and blood pressure reduction, important goals in the management of T2DM.
It is unclear whether some of metformin's benefits may be mediated via GLP-1. To explore this, it is important to establish robustly the effect of metformin on GLP-1, and whether any effect is mediated by changes in related variables such as weight or glycaemia.
Various small studies of short duration have investigated the effect of metformin therapy on circulating GLP-1 levels in individuals with and without T2DM. [13] [14] [15] [16] [17] [18] [19] [20] 
| MATERIALS AND METHODS
The CAMERA study was a randomized double-blind placebocontrolled trial designed to investigate the effect of metformin on surrogate markers of cardiovascular disease in patients without diabetes, aged 35 to 75 years, with established coronary heart disease and a large waist circumference (≥94 cm in men, ≥80 cm in women; NCT00723307 The same commercial kits were used to measure GLP-1 levels as in CAMERA. In DIRECT, the mean intra-and inter-assay CVs for active GLP-1 were 9% and 10%, respectively. For total GLP-1, these CVs were 6% and 9%, respectively.
| Ethics and consent
All participants provided written informed consent for participation in both studies. For the CAMERA study, this included permission for biochemical assays that were not planned at the time of the trial. The 
| Statistics
Normality was assessed for all variables, and non-normally distributed data were transformed using the natural log value where relevant (specifically for active GLP-1, total GLP-1, leptin and HOMA2-IR).
In the CAMERA study, analyses were performed for the modified intention-to-treat population (ie, participants with a baseline total GLP-1 and at least one subsequent total GLP-1 result). The effect of metformin on total GLP-1 was investigated using two different approaches. First, repeated-measures analysis was carried out, allowing a comparison of metformin-and placebo-treated participants over the entire trial (assuming a general covariance structure). Repeatedmeasures analyses were only performed after demonstrating that there was no significant treatment-by-visit interaction (ie, that any observed effect was stable over the trial). Secondly, analyses of covariance were carried out to determine the effect of metformin vs placebo on total GLP-1 levels at 6, 12 and 18 months, respectively.
Additional on-treatment analyses were performed to assess whether any change in total GLP-1 attributable to metformin was related to simultaneous changes in weight, HOMA2-IR, HbA1c, leptin, or all four variables combined, by adding these as cofactors.
In the DIRECT study, fasting active and total GLP-1, and 60-minute post-meal total GLP-1 levels were compared between metformin and lifestyle groups using Student's t-tests. 
| RESULTS
Baseline characteristics of the participants in the CAMERA and DIRECT studies are summarized in Table S1 and Table 1 , respectively.
It was previously reported that metformin led to falls in HbA1c level (0.13% or 1.4 mmol/mol), fasting insulin level (21%), HOMA-IR value (26%) and weight (3.2 kg) compared with placebo over 1.5 years in the CAMERA study.
In the DIRECT study there was no significant difference in age, sex, BMI, duration of diabetes or HbA1c between the metformin and non-metformin treated groups. Metformin-treated individuals had a higher fasting glucose level (P < .001) and a slightly higher waist-hip ratio than those on no treatment (P = .045) in the DIRECT study.
| CAMERA results: Metformin increases fasting total GLP-1 over 18 months
The geometric mean for total GLP-1 was 3.52 pmol/L (11.6 pg/mL) in metformin recipients and 3.76 pmol/L (12.4 pg/mL) in placebo recipients at baseline. Metformin therapy led to significant increases in fasting total GLP-1 levels compared with placebo at each of the 6, 12 and 18-month study visits (Table 2 and Figure 1A ). The increases in total GLP-1 levels at these visits were 21% (P = .010), 27% (P = .001) and 19% (P = .012), respectively. In repeatedmeasures analysis, metformin increased total GLP-1 level by 23.4%
(P < .0001) across the entire duration of the 18-month follow-up, with no evidence of heterogeneity among the study visits (P = .74).
Leptin levels fell with metformin treatment, in keeping with a reduction in body fat (Table 2) . Overall, metformin therapy reduced leptin by 25% (P < .0001) compared with placebo, with similar changes observed at each visit.
Adjustment for the observed changes in weight, HOMA2-IR,
HbA1c and leptin at each visit, whether individually or combined, did not attenuate metformin's effect on total GLP-1 level (Table 3) .
Adjusted comparisons (for all four variables) at 6, 12 and 18 months showed an increase in total GLP-1 level of 32% (P = .001), 35%
(P ≤ .001) and 26% (P = .002), respectively, for metformin compared with placebo therapy.
| DIRECT results: Association of metformin with fasting and post-meal GLP-1 levels
The geometric mean for total fasted GLP-1 level was 2.39 pmol/L in metformin recipients and 2.09 pmol/L in lifestyle-treated patients.
Metformin users had higher basal fasted active GLP-1 levels (+25.5%, 95% confidence interval [CI] 17.0-35.5; P < .001) and fasted total GLP-1 levels (+14.5%, 95% CI 8.4-21.0; P = .0097) than individuals who were on lifestyle therapy (Table 1 and Figure 1B ). These differences persisted after controlling for anthropometric measures (age, sex, waist-hip ratio, BMI), lifestyle factors (smoking, alcohol), study centre and HbA1c for both fasted active and fasted total GLP-1 (+39.1%, 95% CI 21.3-56.4; P = 1.35e-05 and +14.1%, 95% CI 1.2-25.9, respectively; P = .03). Replacing HbA1c with fasting glucose in these models did not materially alter these results. There was no difference in the 60-minute total GLP-1 concentration between metformin users and non-metformin users after adjusting for these covariates and baseline total GLP-1 (4.4%, 95% CI −0.5 to 9.4; P = .27).
| DISCUSSION
In the present two complementary studies we sought further information regarding the relationship between metformin therapy and circulating GLP-1 levels. We showed that daily metformin therapy for 18 months led to a 25% increase in circulating total GLP-1 levels in individuals without diabetes but with elevated waist 1 Analysis of covariance for visits at 6, 12 and 18 months, respectively.
2 Repeated measures analysis for the overall treatment effect over 18 months.
3 Percentage difference in geometric means. circumferences, and this increase was sustained across the entire duration of the study and did not appear to be related to any changes in glycaemia or adiposity. In people with recently diagnosed T2DM, metformin treatment was associated with higher fasted active and fasted total, but not incremental, GLP-1 levels. In both studies, these differences in GLP-1 levels occurred despite the previous dose of metformin having been taken the day before each visit (>24 hours in the DIRECT study), suggesting that circulating GLP-1 levels probably remain consistently elevated in patients on metformin therapy. (Table S2 ). In a study of 10 obese participants without diabetes and 10 control subjects who were given metformin 2.55 g/d for 2 weeks, GLP-1 levels at 30 and 60 minutes after a glucose load were increased though baseline GLP-1 levels (and leptin) and were unchanged on metformin. 13 An uncontrolled study of metformin therapy (2 g/d) in 40 women with polycystic ovarian syndrome over 8 months, albeit with substantial loss to follow-up, with only 22 women completing metformin therapy, produced similar findings to our own, with a 25% increase in area-under-the-curve GLP-1 levels over 180 minutes during oral glucose loading compared with baseline. 14 In a crossover study 10 individuals with T2DM were given 3 single-dose interventions on 3 different days, 1 week apart (either metformin 1 g plus placebo subcutaneous injection or placebo tablet plus subcutaneous GLP-1 or metformin 1 g plus subcutaneous GLP-1). 15 Glucose was infused to achieve a concentration of~15 mmol/L.
Analyses showed that metformin therapy inhibited DPP-4 activity and also increased active GLP-1 levels. In a further crossover study conducted in 20 participants with T2DM who were treated for 6 days with each of four respective regimens (placebo or metformin or sitagliptin or the combination) with washout periods in between interventions, metformin therapy led to an increase in fasted and post-challenge total GLP-1 levels, although there was no change in intact GLP-1 levels. 16 Furthermore, in a crossover study of 12 participants with T2DM treated with placebo or metformin for 7 days, respectively, and then investigated during intraduodenal catheter infusion of glucose, DPP-4 activity fell modestly while intact and total GLP-1 levels rose at baseline and during the infusion after metformin. 17 By contrast, a crossover study of 16 participants with T2DM Results are shown as percentage change in geometric mean (95% CI).
Unadjusted result at each time point is provided, followed by the result adjusted for changes in weight, HOMA2-IR, HbA1c and leptin respectively; this is followed by the result adjusted for all these variables combined (indicated by *).
In summary, we report evidence from 2 major studies showing that metformin treatment leads to a sustained and long-term Table S3 . 
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